According to AMS, the GreenLight XPS is the latest in AMS’ portfolio of technologically advanced solutions to treat enlarged prostate. The new GreenLight XPS offers enhanced treatment efficiency with extended fiber longevity and improved coagulation capabilities over other laser therapy treatment systems.

AMS claimed that the GreenLight has proven to deliver results equivalent to TURP, with lower morbidity, fewer complications, shorter hospital stays and lower overall cost.

The GreenLight XPS improves vaporization efficiency leading to a reduction in treatment time without impacting the depth of tissue removal or coagulation. The XPS system features FiberLife, an automatic safety feature that decreases fiber-related failures by up to 90% resulting in increased longevity, enabling the treatment of glands larger than 100g with a single fiber.

Joe Martin, SVP and GM of BPH Therapies at AMS, said: “GreenLight XPS provides the most compelling alternative to TURP therapies and furthers our commitment to fostering a new standard of care for treating enlarged prostate. With these advances in our GreenLight system, we’re one step closer to realizing our vision of a world without TURP and its bothersome side effects.”

Ricardo Gonzalez, Houston Metro Urology/Baylor College of Medicine, participant in the clinical evaluation of the GreenLight XPS Laser System, said: “The new FiberLife feature improves procedural efficiency and fiber reliability allowing treatment of larger glands with one fiber.”